The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
6 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,414,585 in first-year total cost, median $224,989.
Most frequent study sections
- Special Emphasis Panel[ZRG1 DKUS-L (11)]2
- Special Emphasis Panel[ZRG1 DKUS-N (10)]2
- Special Emphasis Panel[ZRG1 EMNR-W (10)]1
- Special Emphasis Panel[ZRG1 MOSS-U (12)]1
Most frequent institutions
- ANTEANA THERAPEUTICS, INC.1
- CELLF-BIO INC1
- O2 REGENTECH, LLC1
- STEMMED, LTD1
- SUN BIOPHARMA, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2016 | Evaluation of SBP-101 for the Treatment of Acute Pancreatitis1R41DK111337-01 | PANDOL, STEPHEN J.WALKER, MICHAEL | SUN BIOPHARMA, INC., FL | $225,000 | ZRG1 |
| 2016 | OXAID: Oxygenating Hydrogel for Diabetic Wound Care1R41DK105704-01A1 | INMANN, ANDREASLEIPZIG, NIC D | O2 REGENTECH, LLC, OH | $224,977 | ZRG1 |
| 2016 | Oral Small Molecule STAT3 Inhibitor to Treat Cachexia in Chronic Kidney Disease1R42DK104494-01A1 | TWEARDY, DAVID JOHN | STEMMED, LTD, TX | $215,557 | ZRG1 |
| 2015 | Implantation of Bioengineered Intrinsically Innervated Internal Anal Sphincter (BioSphincter) to Treat Fecal Incontinence1R42DK105593-01A1 | BITAR, KHALIL N | CELLF-BIO INC, VA | $225,000 | ZRG1 |
| 2015 | A new treatment for NSAID-associated gastrointestinal damage1R41DK104489-01A1 | PIOMELLI, DANIELE | ANTEANA THERAPEUTICS, INC., CA | $150,000 | ZRG1 |
| 2014 | Development of Compounds for the Prevention and Treatment of Rhabdomyolysis1R41DK104638-01 | OATES, JOHN ALEXANDER | VDDI PHARMACEUTICALS, TN | $374,051 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.